The US Food and Drug Administration (FDA) has granted approval for GE Healthcare’s SenoClaire, a new breast tomosynthesis solution designed with a three-dimensional imaging technology.
With the help of Massachusetts General Hospital, GE has developed SenoClaire technology, which utilizes a low-dose short X-ray sweep around the positioned breast with nine exposures acquired with a step-and-shoot method.
According to GE, there will be no increase in dose from a 2D standard mammogram to a 3D view with SenoClaire, which decreases radiation levels among patients during a breast exam.
SenoClaire, in combination with Centricity PACS and Centricity Clinical Archive solution, allows clinicians in accessing patient’s longitudinal record and provides data to enable better patient care.
GE Healthcare chief marketing officer Catherine Tabaka said that SenoClaire not only offers patients a new solution to help clinicians better detect breast cancer, but does so with low dose radiation and high image quality.
"This new generation technology, breast tomosynthesis, together with innovative solutions like contrast enhanced spectral mammography, automated whole breast ultrasound, and molecular breast imaging will equip healthcare providers with a comprehensive set of tools that will help their patients across the entire breast care continuum," Tabaka added.
GE Healthcare noted that currently it has 180 units installed in Europe, Australia, Latin America, Southeast Asia and the Middle East.
Image: There will be no increase in dose from a 2D standard mammogram to a 3D view with SenoClaire. Photo: courtesy of GE.